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A B S T R A C T
Inﬂuenza A vaccine eﬃcacy in the elderly is generally poor and so identiﬁcation of novel molecular adjuvants to
improve immunogenicity is important to reduce the overall burden of disease. Short non-coding RNAs, known as
microRNAs (miRNAs) are known to regulate gene expression and have the potential to inﬂuence immune
responses. One such miRNA, miR-155, has been shown to modulate T and B cell development and function. We
incorporated miR-155 into the inﬂuenza A virus (IAV) genome creating a self-adjuvanting ‘live vaccine’ with the
ability to modify immunogenicity. Infection of mice with a recombinant inﬂuenza virus encoding miR-155 in the
NS gene segment altered epitope-speciﬁc expansion of inﬂuenza-speciﬁc CD8+ T cells and induced signiﬁcantly
higher levels of neutralising antibody.
1. Introduction
First discovered in Caenorhabditis elegans in 1993, microRNAs
(miRNAs) are short, 19–22 bp, non-coding, single stranded RNA
sequences that bind 3′-untranslated regions (UTRs) of target messenger
RNAs (mRNAs) to regulate gene expression and downstream cellular
functions, including immunity following virus infection (Bakre et al.,
2012, 2013; Meliopoulos et al., 2012).
miR-155, derived from the non-coding transcript of the proto-
oncogene bic (B cell integration cluster) has been implicated in both
direct and indirect regulation of B and T cell development and function
(Lagos-Quintana et al., 2002; Rodriguez et al., 2007). miR-155 is highly
expressed in the thymus and bone marrow and is known to play a
signiﬁcant role in the regulation of CD4+ (Th1, Th2, and Th17), CD8+,
and T regulatory (Tregs) cell function (Martin et al., 2006; Seddiki
et al., 2014; Spoerl et al., 2013). Previous studies have shown that miR-
155-deﬁcient mice fail to establish protection against inﬂuenza infec-
tion due to disrupted cell-mediated and humoral immune responses
(Rodriguez et al., 2007; Thai et al., 2007). Notably, miR-155 expression
in naïve T and B cells is relatively low. It is however upregulated
following TCR or BCR activation suggesting it plays a critical role in
inducing optimal immunity (Turner and Vigorito, 2008).
Inﬂuenza A viruses (IAV) are members of the Orthomyxoviridae
family and cause signiﬁcant morbidity and mortality worldwide.
Eﬃcient IAV clearance is mediated by numerous cell types including
neutrophils, NK cells, dendritic cells, B cells, CD4+ and CD8+ T cells
(Schultz-Cherry, 2015; Huﬀord et al., 2015; Waﬀarn and Baumgarth,
2011). Of particular interest is the fact that establishment of CD8+ T
cell immunity has been associated with reduced viral loads. IAV
infection drives recruitment, activation and diﬀerentiation of CD8+ T
cell precursors (Kaech and Ahmed, 2001) following dendritic cell
antigen processing and presentation (van Stipdonk et al., 2001). Once
activated, eﬀector CD8+ T cells mediate viral clearance through
exocytosis of cytolytic granules containing perforin and granzyme or
via the interaction of FasL and Fas on target cells (Stambas et al., 2008).
Although a large variety of inﬂuenza speciﬁc peptides are available for
MHC Class I presentation to CD8+ T cells in the B6 mouse model, the
DbNP366-374 and DbPA224-233 epitopes dominate the response (Cukalac
et al., 2014).
Diﬀerential expression of miR-155 has been observed at various
stages of CD8+ T cell activation and diﬀerentiation. Enhanced expres-
sion of miR-155 has been noted in both eﬀector and eﬀector memory
CD8+ T cells when compared to naive and central memory counter-
parts. This diﬀerential expression is further supported in vitro following
artiﬁcial activation of CD8+ T cells with anti-CD3 and anti-CD28
antibodies where signiﬁcant up-regulation of miR-155 is detected
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(Podshivalova and Salomon, 2013; Grigoryev et al., 2011). Moreover,
inﬂuenza virus infection of miR-155 knockout mice demonstrates
reduced antigen speciﬁc CD8+ T cells in the lung, spleen and
mediastinal lymph node during the eﬀector phase (Gracias et al.,
2013). Transgenic mice on the other hand overexpressing miR-155
(using an integrating retroviral system not easily translatable to
humans) show a substantial increase in the number of inﬂuenza-speciﬁc
CD8+ T cells when compared to WT controls (Gracias et al., 2013).
The role of miR-155 in regulating CD8+ T cell immunity is not
limited to inﬂuenza A viruses. Selective depletion of miR-155 expres-
sion in CD8+ T cells using a chimeric mouse model prolonged MHV68
viral clearance and enhanced vireamia post infection in a process
thought to be mediated by a reduction in functionally active IFNγ (Tsai
et al., 2013). Along with T cell eﬀector function, miR-155 is thought to
play an important role in the establishment of immunological memory.
High miR-150/miR-155 ratios have been shown to favour development
of a central memory phenotype whilst low miR-150/miR-155 ratios are
thought to encourage diﬀerentiation of eﬀector cells (Almanza et al.,
2010). The exact mechanism and contribution to CD8+ T cell memory
is yet to be deﬁned.
It is well-established that miR-155 also plays a key role in regulation
of B cell and CD4+ T cell diﬀerentiation; cell types involved in humoral
immunity (Lagos-Quintana et al., 2002; Rodriguez et al., 2007; Martin
et al., 2006; Seddiki et al., 2014; Spoerl et al., 2013). Furthermore,
studies had noted that miR-155 expression is upregulated in activated
germinal centres (Thai et al., 2007; Baumjohann and Ansel, 2014) and
antibody class switching can be altered following miR-155 silencing of
activation induced cytidine deaminase (AID) (Rodriguez et al., 2007;
Vigorito et al., 2007). The impact of miR155 on inﬂuenza-speciﬁc
neutralising antibody titres following infection/vaccination is yet to be
Fig. 1. X31-155 induced weight loss and viral replication kinetics. Mice were intranasally infected with 104 PFU X31-155 or X31-WT and weight loss (A) determined as indicated. Lung
viral titres (B) were evaluated by plaque assay. Whole lungs were collected and homogenised on days 3, 5, 7 and 10 post infection. Lung viral titres are depicted as log10 PFU/lung. Three
independent experiments were performed with data presented as the mean ± SD of N= 5 of a representative experiment.
Table 1
Histopathological comparison of X31-155 and X31-WT infection.
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elucidated and is a key area of research given its usefulness as a
correlate of protection (Chiu and Openshaw, 2015).
The relationship between miRNA expression and T and B cell
responses has led to increasing interest in the development of miRNA
therapeutic and vaccine adjuvant platforms. A key limitation is
eﬀective in vivo delivery of miRNAs. miRNAs need to overcome a
number of obstacles to reach targets via systemic routes. For example,
they must avoid degradation by nucleases, phagocytosis by immune
cells, and clearance via kidney ﬁltration (Singh et al., 2011). Moreover,
after site-speciﬁc delivery, cellular uptake of miRNAs must also occur.
Viruses inherently possess the necessary attributes to circumvent these
obstacles and provide a unique and novel platform for delivery (Couto
and High, 2010). A number of virus platforms have been used in the
past to deliver miRNAs, including adenoviruses and lentiviruses. Issues
including but not limited to integration and control of expression have
all been noted as impediments for real world application (Rubinson
et al., 2003; Xia et al., 2002). In 2010, a novel inﬂuenza-based delivery
system was established using reverse genetics to facilitate expression of
miRNAs (Varble et al., 2010). We utilised this system to deliver miR-
155 in cell culture and noted upregulation of IFNβ and IL-6 through
what we believe was targeting of the negative regulator of cytokine
signalling, SOCS1 (Izzard et al., 2014). These initial preliminary
Fig. 2. Analysis of inﬂuenza DbNP366 and DbPA224 tetramer-speciﬁc CD8± T cell responses. Spleen cells were isolated 10 days pi from X31-155 (white bars) and X31-WT (black bars)
infected mice. Spleen cells were analysed based on CD8 expression and epitope speciﬁcity using ﬂuorescently labelled DbNP366 and DbPA224 tetramers. Data are presented as the total
percentage (A) of CD8+tetramer+ splenocytes and total number (B) of CD8+tetramer+ splenocytes. Data represents the mean ± SD of N= 5. *P < 0.05 compared to X31-WT
infection, **P < 0.01 compared to X31-WT infection using a Student's t-test. Three independent experiments were performed and presented as the mean ± SD of N= 5 of a
representative experiment.
Fig. 3. IAV-speciﬁc neutralising antibody titres. Serum was collected from X31-155 and
X31-WT mice at 10 days post infection. Neutralising antibody titres were determined
using a microneutralization assay. Neutralising antibody titres were quantiﬁed as the
serum dilution factor that successfully neutralised 104 PFU of virus. Data represents the
mean ± SD of N= 5. *P < 0.05 compared to X31-WT infection using a Student's t-test.
Three independent experiments were performed with data presented as the mean ± SD
of N= 5 of a representative experiment.
L. Izzard et al. Virus Research 235 (2017) 115–120
117
observations provided support for the use of genetically engineered
miRNA expressing IAVs as potential self-adjuvanting vaccines.
Currently, there are two types of commercially available inﬂuenza A
vaccines; (i) chemically inactivated virus particles known to stimulate
neutralising antibodies against circulating IAV and (ii) live – attenuated
vaccines that activate both T cell and B cell immunity. Although
relatively eﬃcient, these current vaccine strategies have reduced
eﬃcacy in susceptible populations, with eﬃcacy levels as low as 17%
in the elderly, compared to as high as 90% in young adults (Goodwin
et al., 2006). This manuscript describes the use of a recombinant
inﬂuenza virus expressing miR-155 for its ability to modulate adaptive
immunity. We show enhanced inﬂuenza-speciﬁc CD8+ T cells numbers
and neutralising antibody responses in a B6 mouse model of infection.
2. Materials and methods
2.1. Generation and ampliﬁcation of a miR-155 expressing HKx31 (H3N2)
IAV
The miR-155 expressing HKx31 (X31) IAV was rescued using a
modiﬁed non-structural (NS) gene expression plasmid and reverse
genetics protocols as previously described (Izzard et al., 2014). Six
internal PR8 (H1N1) gene segments (including a modiﬁed miR155
encoded NS segment) were transfected into a co-culture of 293T and
MDCK cells along with HKx31 (H3N2) HA and NA gene segments to
create a recombinant HKx31-155 (X31-155) virus. Virus stocks were
ampliﬁed in 10-day embryonated eggs, and virus titres were deter-
mined using a plaque assay.
2.2. Infection and sample collection
Intranasal infections were performed in C57.BL/6 mice as pre-
viously described (Stambas et al., 2007). Brieﬂy, naive 8-wk old
C57.BL/6 mice were anesthetised with isoﬂurane before intranasal
(i.n.) infection with 104 plaque forming units (PFU) wild type HKx31
(H3N2) IAV (X31-WT), or a modiﬁed HKx31 (H3N2) IAV expressing
miR-155 (X31-155). Mice from the X31-WT and X31-155 groups were
euthanized at days 1, 3, 5, 7, and 10 pi, and lungs and spleen harvested
for analyses. Single cell suspensions of spleen cells were prepared and
red blood cell lysis performed using a Tris-buﬀered Ammonium
Chloride (ATC) solution (0.14 M NH4Cl, 0.017 M Tris, pH 7.2) prior
to tetramer analysis.
2.3. Lung virus titres
Lung viral titres was determined by plaque assay. Brieﬂy, 6-well
plates (Thermo Fisher Scientiﬁc, Australia) containing conﬂuent MDCK
cell monolayers were infected with lung homogenate for 45 mins at
37 °C. Following this, 3 ml of overlay media [L15 media (Life
Technologies, Australia), 0.025% NaHCO3, 0.4 mM HEPES, 100 U/ml
Penicillin/Streptomycin (Life Technologies, Australia), 24 μg/ml
Gentamycin (Life Technologies, Australia), 1 mg/ml TPCK treated
trypsin (Worthington Biochemical Corporation, USA) and 0.8% agarose
(Sigma–Aldrich, Australia)] was added to the wells. Plates were
incubated at 37 °C, 5% CO2 for 72 h and stained with crystal violet
(0.1% in 20% ethanol) to visualise and enumerate plaques.
2.4. Flow cytometry analysis
For tetramer analysis, enriched spleen cells were incubated with
either DbNP366 or DbPA224-speciﬁc tetramers (Altman et al., 1996) for
60 min at room temperature. Enriched cells were centrifuged and
resuspended in RPMI 1640 medium (Gibco, Australia) containing
100 U/ml Penicillin/Streptomycin (Life Technologies, Australia),
24 μg/ml Gentamycin (Life Technologies, Australia) and 10% FCS.
Cells were subsequently washed and stained with anti-mouse CD8α-
PerCP Cy5.5 (BD Biosciences, Australia) for 30 min on ice. Following
staining, cells were washed twice with PBS containing 1% BSA and
0.02% NaN2, and analysed by ﬂow cytometry on a BD Fortessa (BD
Biosciences, Australia).
2.5. Histopathology
Lung samples were ﬁxed in a 10% Neutral Buﬀered Formalin (NBF)
solution overnight (Australian Biostain P/L, Australia) to preserve
morphology and prevent autolysis. Lungs were processed to remove
water and mounted in paraﬃn wax before sectioned using a Leica
Rotary Microtome (Leica Biosystems, Australia). Sections were stained
with Haematoxylin & Eosin and anti-inﬂuenza NP antibody to detect
the presence of IAV.
2.6. Microneutralization assay
Levels of neutralising antibodies were determined using a micro-
neutralization assay adapted from a previously published method
(Harmon et al., 1988). Brieﬂy, heat inactivated mouse serum was
serially diluted in infection media [RPMI (Life Technologies, Australia)
containing 100 U/ml Penicillin/Streptomycin (Life Technologies, Aus-
tralia), 24 μg/ml Gentamycin (Life Technologies, Australia) and 1 mg/
ml TPCK treated trypsin (Worthington Biochemical Corporation, USA)]
in a 96 well plate (Thermo Fisher Scientiﬁc, Australia). HKx31 (H3N2)
IAV (500 PFU) was then added to each well and the plate incubated at
37 °C, 5% CO2 for 1 h. The cell supernantant (100 μl) was then
transferred to a 96 well plate containing conﬂuent monolayer of MDCK
cells and incubated at 37 °C, 5% CO2 for 72 h. Virus was detected using
a standard hemagglutination (HA) assay (Frank et al., 1980).
3. Results
3.1. Weight loss and viraemia
Weight loss is an indicator of IAV pathogenesis and typically peaks
at days 6–7 post-infection (pi). Intranasal infection of C57.BL/6 mice
with 104 pfu X31-155 or X31-WT control viruses showed comparable
weight loss in both groups (peaking at 7 days pi) followed by consistent
weight gain until euthanasia 10 days pi (Fig. 1a). Lung viral titres were
assessed using plaque assay analysis from samples collected at days 1,
3, 7 and 10 pi. Mice infected with X31-155 or X31-WT virus exhibited
comparable viral titres at all four time-points (Fig. 1b). Histopatholo-
gical analysis of lungs collected at day 3 pi showed no substantial
diﬀerences between the two groups (Table 1).
3.2. X31-155 infection results in enhanced CD8+DbNP366 speciﬁc T cell
responses in the spleen
The contribution of CD8+ T cells to IAV immunity and clearance is
well-established. As such, the number of IAV-speciﬁc CD8+ T cells
using DbNP366 or DbPA224 tetramers was determined in the spleens of
infected mice. Flow cytometric analysis showed a signiﬁcant increase in
the percentage and number of CD8+DbNP366 T-cells in the spleen of
mice infected with X31-155 compared to X31-WT controls (Fig. 2). In
contrast, the CD8+DbPA224 T-cell response remained unchanged be-
tween the two groups.
3.3. Expression of miR-155 enhances IAV-speciﬁc humoral immunity
The majority of neutralising antibodies generated to IAV are
directed against the HA and NA glycoproteins. We determined neu-
tralising antibody titres in our experimental groups using a standard
micro-neutralisation assay (Frank et al., 1980). X31-155 infected mice
produced higher neutralising antibody titres when compared to X31-
WT controls (Fig. 3).
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4. Discussion
Previously studies from our group have shown that incorporation of
miR-155 into the NS gene segment of IAV results in modulation of the
antiviral response in vitro (Izzard et al., 2014). Here, we present data
that demonstrates expression of miR-155 enhances cell-mediated im-
munity in mice.
IAV-speciﬁc T cell responses are critical for viral clearance. The
magnitude and speciﬁcity of the CD8+ T cell response is inﬂuenced by
multiple host and viral determinants (Bender et al., 1992). A highly
reproducible immunological hierarchy establishes epitope-speciﬁc re-
sponses against IAV that are dependent on peptide presentation via
MHC class I molecules (Yewdell and Bennink, 1999). Naive antigen-
speciﬁc CD8+ precursor T cell frequency contributes to the magnitude
and hierarchy of epitope-speciﬁc responses (La Gruta et al., 2006)
however precursor frequency alone does not independently determine
the hierarchy of the CD8+ response (La Gruta et al., 2010). Additional
studies have determined that the magnitude and speciﬁcity of the
response is also dependent on the recruitment and proliferative
capacity of distinct epitope-speciﬁc precursor subpopulations (La
Gruta et al., 2010). Furthermore, magnitude can be inﬂuenced by
MHC class I expression on dendritic cells, peptide stability and TCR
avidity (Cukalac et al., 2014; Dinter et al., 2015). We now suggest that
miRNA expression adds an additional layer of complexity to this
equation.
It is well established that primary infection with X31 virus normally
results in co-dominant DbNP366 and DbPA224 CD8+ T cell responses at
10 days post infection (Stambas et al., 2007). Our primary infection
studies using a recombinant X31-155 virus drive an increase in the
magnitude of only the DbNP366-speciﬁc CD8+ T cell response. This
observation suggests that miR-155 is enhancing CD8+DbNP366 T cell
immunity with no overt inﬂuence on CD8 + DbPA224 T cell responses.
Data in Fig. 1 also indicated a trend for improved body weight and
lower virus titres between 7 and 10 days post primary infection
(although this was not statistically signiﬁcant). Given the signiﬁcant
increases in cellular immunity normally associated with secondary
infection, we would expect detectable and statistically signiﬁcant
changes in weight loss and lung virus tires to be observed. The direct
or indirect mechanism by which miR-155 enhances DbNP366-speciﬁc
responses is yet to be determined. We observe no substantial diﬀerences
in viral titres for the X31-155 or X31 WT viruses and can therefore
assume that expression of NP and PA protein is similar. C57BL/6 mice
are inbred and so antigen-speciﬁc precursor frequencies should remain
constant. From this we can assume that the increase observed in
CD8 + DbNP366-speciﬁc T cell responses is unlikely to be solely
attributed to changes in precursor frequency and/or antigen load. It
is more likely that expression of miR-155 from our recombinant virus is
altering MHC class I antigen presentation through modulation of the
microenvironment in the lung or through expression in infected DCs.
Further support for this mechanism of action is derived from studies
that demonstrate a decrease in MHC class II expression on dendritic
cells when miR-155 is knocked down (Li et al., 2014). Our previous
studies have shown that in vitro infection of epithelial cells with PR8-
155 can reduce expression of SOCS1 enhancing expression of IFN beta
and IL-6 (Izzard et al., 2014). As such in vivo infection with X31-155
may alter the cytokine microenvironment in the lung resulting in
disturbances in DC activation, peptide processing, and antigen pre-
sentation.
miR-155 was initially identiﬁed for its contribution to B cell
immunity (Rodriguez et al., 2007). It is upregulated in germinal centre
B cells and potentially protects high aﬃnity cells from apoptosis
through inhibition of the pro-apoptotic protein, JARID2 (Nakagawa
et al., 2016). Additionally, miR-155 helps facilitate follicular T helper
cell congregation in germinal centres (Hu et al., 2014). In our studies,
infection with X31-155 resulted in increased IAV-speciﬁc neutralising
antibody titres. Although the mechanism for the increased antibody
titres remains to be investigated, it is possible that exogenous miR-155
is indirectly contributing to enhanced expression of serum neutralising
antibodies through regulation of B cell maturation or function.
5. Conclusions
In conclusion, we have demonstrated that inclusion of the miR-155
hairpin from the non-structural gene segment of IAV enhances
DbNP366+ CD8+ T cell responses and inﬂuenza-speciﬁc neutralising
antibody activity following primary infection. These novel ﬁndings
highlight the potential use of miRNAs as molecular adjuvants for IAV
vaccines in a self-adjuvanting capacity.
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